Mechanisms of enhanced aggregation and fibril formation of Parkinson’s disease-related variants of α-synuclein

被引:0
|
作者
Takashi Ohgita
Norihiro Namba
Hiroki Kono
Toshinori Shimanouchi
Hiroyuki Saito
机构
[1] Kyoto Pharmaceutical University,Department of Biophysical Chemistry
[2] Okayama University,Graduate School of Environmental and Life Science
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Aggregation of α-synuclein (α-syn) into amyloid fibrils is closely associated with Parkinson’s disease (PD). Familial mutations or posttranslational truncations in α-syn are known as risk factor for PD. Here, we examined the effects of the PD-related A30P or A53T point mutation and C-terminal 123–140 or 104–140 truncation on the aggregating property of α-syn based on the kinetic and thermodynamic analyses. Thioflavin T fluorescence measurements indicated that A53T, Δ123‒140, and Δ104–140 variants aggregated faster than WT α-syn, in which the A53T mutation markedly increases nucleation rate whereas the Δ123‒140 or Δ104‒140 truncation significantly increases both nucleation and fibril elongation rates. Ultracentrifugation and western blotting analyses demonstrated that these mutations or truncations promote the conversion of monomer to aggregated forms of α-syn. Analysis of the dependence of aggregation reaction of α-syn variants on the monomer concentration suggested that the A53T mutation enhances conversion of monomers to amyloid nuclei whereas the C-terminal truncations, especially the Δ104–140, enhance autocatalytic aggregation on existing fibrils. In addition, thermodynamic analysis of the kinetics of nucleation and fibril elongation of α-syn variants indicated that both nucleation and fibril elongation of WT α-syn are enthalpically and entropically unfavorable. Interestingly, the unfavorable activation enthalpy of nucleation greatly decreases for the A53T and becomes reversed in sign for the C-terminally truncated variants. Taken together, our results indicate that the A53T mutation and the C-terminal truncation enhance α-syn aggregation by reducing unfavorable activation enthalpy of nucleation, and the C-terminal truncation further triggers the autocatalytic fibril elongation on the fibril surfaces.
引用
收藏
相关论文
共 50 条
  • [1] Mechanisms of enhanced aggregation and fibril formation of Parkinson's disease-related variants of α-synuclein
    Ohgita, Takashi
    Namba, Norihiro
    Kono, Hiroki
    Shimanouchi, Toshinori
    Saito, Hiroyuki
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [2] PIP3 interacts with alpha-synuclein and initiates its aggregation of Parkinson's disease-related fibril polymorphism
    Ikenaka, Kensuke
    Choong, Chi-Jing
    Aguirre, Cesar
    Kakuda, Keita
    Mochizuki, Hideki
    [J]. JOURNAL OF NEUROCHEMISTRY, 2023, 166 : 78 - 78
  • [3] Phosphatidylinositol-3,4,5-trisphosphate interacts with alpha-synuclein and initiates its aggregation and formation of Parkinson's disease-related fibril polymorphism
    Choong, Chi-Jing
    Aguirre, Cesar
    Kakuda, Keita
    Beck, Goichi
    Nakanishi, Hiroki
    Kimura, Yasuyoshi
    Shimma, Shuichi
    Nabekura, Kei
    Hideshima, Makoto
    Doi, Junko
    Yamaguchi, Keiichi
    Nakajima, Kichitaro
    Wadayama, Tomoya
    Hayakawa, Hideki
    Baba, Kousuke
    Ogawa, Kotaro
    Takeuchi, Toshihide
    Badawy, Shaymaa Mohamed Mohamed
    Murayama, Shigeo
    Nagano, Seiichi
    Goto, Yuji
    Miyanoiri, Yohei
    Nagai, Yoshitaka
    Mochizuki, Hideki
    Ikenaka, Kensuke
    [J]. ACTA NEUROPATHOLOGICA, 2023, 145 (05) : 573 - 595
  • [4] Phosphatidylinositol-3,4,5-trisphosphate interacts with alpha-synuclein and initiates its aggregation and formation of Parkinson’s disease-related fibril polymorphism
    Chi-Jing Choong
    César Aguirre
    Keita Kakuda
    Goichi Beck
    Hiroki Nakanishi
    Yasuyoshi Kimura
    Shuichi Shimma
    Kei Nabekura
    Makoto Hideshima
    Junko Doi
    Keiichi Yamaguchi
    Kichitaro Nakajima
    Tomoya Wadayama
    Hideki Hayakawa
    Kousuke Baba
    Kotaro Ogawa
    Toshihide Takeuchi
    Shaymaa Mohamed Mohamed Badawy
    Shigeo Murayama
    Seiichi Nagano
    Yuji Goto
    Yohei Miyanoiri
    Yoshitaka Nagai
    Hideki Mochizuki
    Kensuke Ikenaka
    [J]. Acta Neuropathologica, 2023, 145 : 573 - 595
  • [5] Structural Insights into α-Synuclein Fibril Polymorphism: Effects of Parkinson's Disease-Related C-Terminal Truncations
    Ni, Xiaodan
    McGlinchey, Ryan P.
    Jiang, Jiansen
    Lee, Jennifer C.
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2019, 431 (19) : 3913 - 3919
  • [6] Parkinson's Disease-Related Protein, α-Synuclein, in Malignant Melanoma
    Matsuo, Yasuhiro
    Kamitani, Tetsu
    [J]. PLOS ONE, 2010, 5 (05):
  • [7] Effects of antioxidant compounds on α-synuclein fibril formation in Parkinson's disease in vitro
    Oropallo, Alexis
    Hillwig, Matthew
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [8] Physicochemical mechanisms of aggregation and fibril formation of α-synuclein and apolipoprotein A-I
    Ohgita, Takashi
    Kono, Hiroki
    Namba, Norihiro
    Saito, Hiroyuki
    [J]. BIOPHYSICS AND PHYSICOBIOLOGY, 2024, 21 (01)
  • [9] α-Synuclein aggregation and Parkinson's disease:: Factors affecting the aggregation of α-synuclein
    Jin, L
    Yang, H
    [J]. PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2006, 33 (04) : 321 - 328
  • [10] Parkinson's disease-related phosphorylation at Tyr39 rearranges α-synuclein amyloid fibril structure revealed by cryo-EM
    Zhao, Kun
    Lim, Yeh-Jun
    Liu, Zhenying
    Long, Houfang
    Sun, Yunpeng
    Hu, Jin-Jian
    Zhao, Chunyu
    Tao, Youqi
    Zhang, Xing
    Li, Dan
    Li, Yan-Mei
    Liu, Cong
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (33) : 20305 - 20315